Le Lézard
Classified in: Science and technology
Subjects: Funding, Company Name Change

Ivo, a Generative AI Legal Contracting Solution, Raises $4.8M to Accelerate Expansion of Existing Platform


Today, Ivo (formerly Latch), a generative AI-powered contract review solution, announced $4.8M in funding to further enable legal teams to improve efficiency and accuracy, ensure consistent negotiating positions and deliver faster business value. To signify the next stage of the company's development, the company is now relaunched under the name Ivo, inspired by Ivo of Kermartin, the patron saint of lawyers. Current Ivo customers include Automattic (WordPress and Tumblr), Carparts.com, Pipe, SCAN Health, Commure, and others.

Ivo will utilize this new round of funding to expand its core team and continue to drive innovation within its existing product offering. The round was led by Uncork Capital and Fika Ventures, with additional funding from previous investors Daniel Gross, GD1, and Phase One Ventures. This brings the company's total funding to $6.2M.

"Contracts are foundational to commerce, but reviewing contracts is a key bottleneck for important business processes. By using AI to reduce the time, effort, and cost of negotiating contracts, we're making it easier for businesses to work together. I'm excited to work with our team to continue pushing the frontiers of AI applications in contracting," said Ivo co-founder and CEO Min-Kyu Jung.

The average lawyer spends between 40-60% of their time drafting and reviewing contracts. Contract professionals spend between one and six hours tracking obligations in a contract over the course of the lifetime of that contract. Ivo utilized the power of generative AI to create a solution for an efficient, accurate contract review process. GPS fleet management company Geotab utilizes Ivo to improve their efficiency. "We saved an average of 45 minutes of review time per contract, which translated into a 75% overall efficiency gain," said David Torchetti, Legal Counsel at Geotab.

To further deliver on the company's vision to reduce inefficiencies in the contract review process, Ivo also announced a series of key updates today, including:

Additionally, Ivo announced that it has obtained the SOC 2 Type II certification, as part of its ongoing commitment to security and operational excellence.

For more information, visit ivo.ai.

About Ivo

Ivo transforms how organizations review their legal contracts by leveraging generative AI to ensure increased efficiency, accuracy, and consistent negotiating positions. This empowers legal teams to reduce tedious workstreams and more effectively review legal contracts at scale. Headquartered in San Francisco, Ivo, formerly known as Latch, is supported by investors including Uncork Capital, Fika Ventures, Daniel Gross, GD1, and Phase One Ventures. Discover the future of AI-powered contract review and request a demo at ivo.ai.


These press releases may also interest you

at 18:00
BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to...

at 17:45
Celonis, the global leader in Process Mining, today announced it has appointed Mark Jacobs to the role of Senior Vice President North America Sales. As the Go-to-Market leader for North America, Jacobs will work closely with new and existing...

at 17:05
DXC Technology , a leading Fortune 500 global technology services company, today announced it will participate in the following investor conferences: J.P. Morgan's Technology, Media, & Telecom 2024 Conference ? Raul Fernandez, President and CEO, is...

at 17:05
Intercontinental Exchange, Inc. ("ICE") announced today that it is commencing a private exchange offer (the "Exchange Offer") with respect to the outstanding 3.625% Senior Notes due 2028 (the "BK Notes") issued by Black Knight InfoServ, LLC, a...

at 17:00
Spyre Therapeutics, Inc. (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel...

at 17:00
Sentynl...



News published on and distributed by: